Barcelona15% of all breast cancer cases diagnosed in the world are of the metastatic HER2+ (HER2+) type, which is characterized by high aggressiveness and
Tremendous progress has been made in the treatment landscape for HER2-positive breast cancer that has significantly altered and improved the outlook for this patient population.
The WIN-B is a Phase Ib/II investigator-sponsored trial (IST) that will evaluate the safety and preliminary efficacy of the Debiopharm's potent Wee-1 inhibitor Debio 0123 in combination with Gilead's
Javier Cortés, MD, PhD, expands on the importance of investigating the central nervous system activity of trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases; key efficacy data from the pooled analysis of the agent in the DESTINY-Breast01, -02 and -03 trials; and more.